Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy

Bone Marrow Transplantation

Volumn 30, Issue 3, 2002, Pages 135-140

  Anderson, C P ^a   Reynolds, C P ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Alkylator resistance; Buthionine sulfoximine; Glutathione; Melphalan; Neuroblastoma

Indexed keywords

BUTHIONINE SULFOXIMINE; CARBOPLATIN; ETOPOSIDE; GLUTATHIONE; MELPHALAN; MYELOABLATIVE AGENT; NSC 326321; PROTEIN P53; SARCOLYSIN; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOTRANSPLANTATION; CANCER GROWTH; CANCER RECURRENCE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE FUNCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; TUMOR CELL LINE; WHOLE BODY RADIATION; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; RECURRENT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTHIONINE SULFOXIMINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLUTATHIONE; HUMANS; MELPHALAN; MYELOABLATIVE AGONISTS; NEUROBLASTOMA; RECURRENCE; TUMOR CELLS, CULTURED;

EID: 0036671651     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703605     Document Type: Article

References (40)

1. Neuroblastoma
2. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
3. Current aspects of biology, risk assessment, and treatment of neuroblastoma
4. Biology and treatment of neuroblastoma
5. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival
6. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study
7. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid
8. Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines
9. Preclinical and clinical modulation of anticancer drugs
10. The role of thiols in cellular response to radiation and drugs
11. Glutathione
12. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs
13. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion
14. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
15. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy
16. Buthionine sulfoximine (BSO) is cytotoxic and enhances the activity of melphalan for human neuroblastoma cell lines
17. Depletion of glutathione (GSH) by buthionine sulfoximine (BSO) is cytotoxic for human neuroblastoma cell lines via apoptosis
18. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione
19. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
20. Pilot study of buthionine sulfoximine (BSO) and melphalan (L-PAM) in children with recurrent neuroblastoma
21. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results
22. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment
23. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
24. Biological classification of cell lines derived from human extra-cranial neural tumors
25. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in melphalan-resistant neuroblastoma cell line
26. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates
27. Cytotoxic activity of deferoxamine and hydroxyurea for neuroblastoma in vitro
28. Drug resistance patterns in human neuroblastoma cell lines correlates with clinical therapy
29. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
30. Characterization of human neuroblastoma cell lines established before and after therapy
31. Dose effect analysis with microcomputers
32. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
33. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
34. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems
35. Relationships between inhibition constants and fractional inhibitions in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types of mechanisms of inhibition
36. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: Performance study of a new miniaturized protocol
37. Buthionine sulfoximine (BSO) and melphalan (L-Pam) is active against recurrent neuroblastoma
38. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: An Eastern Cooperative Oncology Group (ECOG) study
39. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation
40. Pharmacokinetics of high dose melphalan